Search

Your search keyword '"Sedek Ł"' showing total 9 results
Start Over Author "Sedek Ł"
9 results on '"Sedek Ł"'

1. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

Author

Lhermitte, Ludovic, Barreau, Sylvain, Morf, Daniela, Fernandez, Paula, Grigore, Georgiana, Barrena, Susana, de Bie, Maaike, Flores-Montero, Juan, Brüggemann, Monika, Mejstrikova, Ester, Nierkens, Stefan, Burgos, Leire, Caetano, Joana, Gaipa, Giuseppe, Buracchi, Chiara, da Costa, Elaine Sobral, Sedek, Lukasz, Szczepański, Tomasz, Aanei, Carmen-Mariana, van der Sluijs-Gelling, Alita, Delgado, Alejandro Hernández, Fluxa, Rafael, Lecrevisse, Quentin, Pedreira, Carlos E., van Dongen, Jacques J.M., Orfao, Alberto, van der Velden, Vincent H.J., van Dongen, J. J.M., Bitter, W.M., Lubbers, B.R., Teodosio, C.I., Zlei, M., van der Sluijs-Gelling, A.J., de Bie, F., de Bruin-Versteeg, S., van der Burg, M., Schilham, M.W., van der Velden, V. H.J., Langerak, A.W., te Marvelde, J., Bras, A.E., Schilperoord-Vermeulen, J., Jugooa, R., Heezen, K.C., Orfao, A., Almeida, J., Vidriales, M.B., Flores-Montero, J., Pérez-Andrés, M., Matarraz, S., Martín, L., Lecrevisse, Q., Pérez-Morán, J.J., Puig, N., Almeida, A. Medina, Gomes da Silva, M., Faria, T., Brüggemann, M., Ritgen, M., Szczepanowski, M., Kohlscheen, S., Laqua, A., Harbst, E., Finke, J., Asnafi, V., Lhermitte, L., Duroyon, E., Trka, J., Hrusak, O., Kalina, T., Mejstrikova, E., Novakova, M., Thurner, D., Kanderova, V., Szczepanski, T., Sędek, L., Bulsa, J., Slota, L., Kulis, J., Pedreira, C.E., da Costa, E. Sobral, Nierkens, S., de Jong, A., de Koning, A., Lima, M., Santos, A.H., Böttcher, S., Lange, S., Engelmann, R., Paape, D., Machka, C., Gaipa, G., Burracchi, C., Bugarin, C., Lopez-Granados, E., del Pino Molina, L., Campos-Guyotat, L., Aanei, C., Miguel, J. F. San, Paiva, B., Burgos, L., Villamor-Casas, N., Magnano, L., Philippé, J., Bonroy, C., Denys, B., Willems, A., Breughe, P., de Wolf, J., Sousa, A.E., Silva, S.L., Fernandez, P., and Morf, D.

Published
2021
Full Text
View/download PDF

2. Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome

Author

Oliveira, E, Costa, E, Ciudad, J, Gaipa, G, Sedek, Ł, Barrena, S, Szczepanski, T, Buracchi, C, Silvestri, D, Siqueira, P, Mello, F, Torres, R, Oliveira, L, Fay-Neves, I, Sonneveld, E, van der Velden, V, Mejstrikova, E, Ribera, J, Conter, V, Schrappe, M, van Dongen, J, Land, M, Orfao, A, Oliveira, E, Costa, E, Ciudad, J, Gaipa, G, Sedek, Ł, Barrena, S, Szczepanski, T, Buracchi, C, Silvestri, D, Siqueira, P, Mello, F, Torres, R, Oliveira, L, Fay-Neves, I, Sonneveld, E, van der Velden, V, Mejstrikova, E, Ribera, J, Conter, V, Schrappe, M, van Dongen, J, Land, M, and Orfao, A

Abstract

For the last two decades, measurable residual disease (MRD) has become one of the most powerful independent prognostic factors in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, the effect of therapy on the bone marrow (BM) microenvironment and its potential relationship with the MRD status and disease free survival (DFS) still remain to be investigated. Here we analyzed the distribution of mesenchymal stem cells (MSC) and endothelial cells (EC) in the BM of treated BCP-ALL patients, and its relationship with the BM MRD status and patient outcome. For this purpose, the BM MRD status and EC/MSC regeneration profile were analyzed by multiparameter flow cytometry (MFC) in 16 control BM (10 children; 6 adults) and 1204 BM samples from 347 children and 100 adult BCP-ALL patients studied at diagnosis (129 children; 100 adults) and follow-up (824 childhood samples; 151 adult samples). Patients were grouped into a discovery cohort (116 pediatric BCP-ALL patients; 338 samples) and two validation cohorts (74 pediatric BCP-ALL, 211 samples; and 74 adult BCP-ALL patients; 134 samples). Stromal cells (i.e., EC and MSC) were detected at relatively low frequencies in all control BM (16/16; 100%) and in most BCP-ALL follow-up samples (874/975; 90%), while they were undetected in BCP-ALL BM at diagnosis. In control BM samples, the overall percentage of EC plus MSC was higher in children than adults (p = 0.011), but with a similar EC/MSC ratio in both groups. According to the MRD status similar frequencies of both types of BM stromal cells were detected in BCP-ALL BM studied at different time points during the follow-up. Univariate analysis (including all relevant prognostic factors together with the percentage of stromal cells) performed in the discovery cohort was used to select covariates for a multivariate Cox regression model for predicting patient DFS. Of note, an increased percentage of EC (>32%) within the BCP-ALL BM stromal cell compartment at day +78 of

Published
2022

4. Powierzchniowa ekspresja receptora TSLPR (CRLF2) maskuje predykcyjny wpływ delecji genu IKZF1 na poziom minimalnej choroby resztkowej w trakcie indukcji remisji dziecięcej ostrej białaczki limfoblastycznej (ALL)

Author

Pastorczak, A., Sędek, Ł., Braun, M., Madzio, J., Sonsala, A., Fendler, W., Chmielewska, M., Taha, J., Górniak, P., Romiszewska, M., Matysiak, M., Derwich, K., Lejman, M., Kowalczyk, J., Badowska, W., Niedźwiedzki, M., Kazanowska, B., Szczepański, T., and Młynarski, W.

Published
2015
Full Text
View/download PDF

7. Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome

Author

Oliveira, Elen, Costa, Elaine S., Ciudad Pizarro, Juana, Gaipa, Giuseppe, Sedek, Łukasz, Barrena, Susana, Szczepanski, Tomasz, Buracchi, Chiara, Silvestri, Daniela, Siqueira, Patricia F.R., Mello, Fabiana V., Torres, Rafael C., Oliveira, Leonardo M.R., Fay-Neves, Isabelle V.C., Sonneveld, Edwin, Van der Velden, Vincent, Mejstrikova, Esther, Ribera, Jose-Maria, Conter, Valentino, Schrappe, Martin, van Dongen, Jacques J.M., Land, Marcelo G.P., Orfao, Alberto, Universitat Autònoma de Barcelona, Oliveira, E, Costa, E, Ciudad, J, Gaipa, G, Sedek, Ł, Barrena, S, Szczepanski, T, Buracchi, C, Silvestri, D, Siqueira, P, Mello, F, Torres, R, Oliveira, L, Fay-Neves, I, Sonneveld, E, van der Velden, V, Mejstrikova, E, Ribera, J, Conter, V, Schrappe, M, van Dongen, J, Land, M, Orfao, A, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brasil), Fundaçao Capes (Brasil), Ministerio de Educación, Cultura y Deporte (España), Centro de Investigación Biomédica en Red Cáncer (España), Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brasil), and Immunology

Subjects
bone marrow microenvironment, mesenchymal stem cells, Cancer Research, measurable residual disease, multiparameter flow cytometry, Endothelial cells, B-cell precursor acute lymphoblastic leukemia, stromal cells, endothelial cells, disease free survival, stromal cell, Oncology, SDG 3 - Good Health and Well-being, endothelial cell, Mesenchymal stem cells, Stromal cells, mesenchymal stem cell
Abstract

For the last two decades, measurable residual disease (MRD) has become one of the most powerful independent prognostic factors in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, the effect of therapy on the bone marrow (BM) microenvironment and its potential relationship with the MRD status and disease free survival (DFS) still remain to be investigated. Here we analyzed the distribution of mesenchymal stem cells (MSC) and endothelial cells (EC) in the BM of treated BCP-ALL patients, and its relationship with the BM MRD status and patient outcome. For this purpose, the BM MRD status and EC/MSC regeneration profile were analyzed by multiparameter flow cytometry (MFC) in 16 control BM (10 children; 6 adults) and 1204 BM samples from 347 children and 100 adult BCP-ALL patients studied at diagnosis (129 children; 100 adults) and follow-up (824 childhood samples; 151 adult samples). Patients were grouped into a discovery cohort (116 pediatric BCP-ALL patients; 338 samples) and two validation cohorts (74 pediatric BCP-ALL, 211 samples; and 74 adult BCP-ALL patients; 134 samples). Stromal cells (i.e., EC and MSC) were detected at relatively low frequencies in all control BM (16/16; 100%) and in most BCP-ALL follow-up samples (874/975; 90%), while they were undetected in BCP-ALL BM at diagnosis. In control BM samples, the overall percentage of EC plus MSC was higher in children than adults (p = 0.011), but with a similar EC/MSC ratio in both groups. According to the MRD status similar frequencies of both types of BM stromal cells were detected in BCP-ALL BM studied at different time points during the follow-up. Univariate analysis (including all relevant prognostic factors together with the percentage of stromal cells) performed in the discovery cohort was used to select covariates for a multivariate Cox regression model for predicting patient DFS. Of note, an increased percentage of EC (>32%) within the BCP-ALL BM stromal cell compartment at day +78 of therapy emerged as an independent unfavorable prognostic factor for DFS in childhood BCP-ALL in the discovery cohort—hazard ratio (95% confidence interval) of 2.50 (1–9.66); p = 0.05—together with the BM MRD status (p = 0.031). Further investigation of the predictive value of the combination of these two variables (%EC within stromal cells and MRD status at day +78) allowed classification of BCP-ALL into three risk groups with median DFS of: 3.9, 3.1 and 1.1 years, respectively (p = 0.001). These results were confirmed in two validation cohorts of childhood BCP-ALL (n = 74) (p = 0.001) and adult BCP-ALL (n = 40) (p = 0.004) treated at different centers. In summary, our findings suggest that an imbalanced EC/MSC ratio in BM at day +78 of therapy is associated with a shorter DFS of BCP-ALL patients, independently of their MRD status. Further prospective studies are needed to better understand the pathogenic mechanisms involved., This research was supported by the EuroFlow Consortium and by the following grants: Bilateral Cooperation Program between Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-CAPES (Brasília/Brazil) and Dirección General de Políticas Universitárias-Ministério de Educación, Cultura y Deportes-DPGU (Madrid/Spain) (311/15); Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC; Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid, Spain and FONDOS FEDER) and PI (Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid, Spain and Fondos FEDER); Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro of Brazil(E26/110.105/2014; E26/102.191/2013); Conselho Nacional de Desenvolvimento Científico e Tecnológico-CNPQ of Brazil (400194/2014–7) and Instituto Desiderata/Chevron, Rio de Janeiro, Brazil, by the grant “Actions to improve pediatric cancer assistance in RJ”. EO was supported by a grant from CAPES (Brazil).

Published
2022

8. Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome.

Author

Oliveira E, Costa ES, Ciudad J, Gaipa G, Sedek Ł, Barrena S, Szczepanski T, Buracchi C, Silvestri D, Siqueira PFR, Mello FV, Torres RC, Oliveira LMR, Fay-Neves IVC, Sonneveld E, van der Velden VHJ, Mejstrikova E, Ribera JM, Conter V, Schrappe M, van Dongen JJM, Land MGP, and Orfao A

Abstract

For the last two decades, measurable residual disease (MRD) has become one of the most powerful independent prognostic factors in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, the effect of therapy on the bone marrow (BM) microenvironment and its potential relationship with the MRD status and disease free survival (DFS) still remain to be investigated. Here we analyzed the distribution of mesenchymal stem cells (MSC) and endothelial cells (EC) in the BM of treated BCP-ALL patients, and its relationship with the BM MRD status and patient outcome. For this purpose, the BM MRD status and EC/MSC regeneration profile were analyzed by multiparameter flow cytometry (MFC) in 16 control BM (10 children; 6 adults) and 1204 BM samples from 347 children and 100 adult BCP-ALL patients studied at diagnosis (129 children; 100 adults) and follow-up (824 childhood samples; 151 adult samples). Patients were grouped into a discovery cohort (116 pediatric BCP-ALL patients; 338 samples) and two validation cohorts (74 pediatric BCP-ALL, 211 samples; and 74 adult BCP-ALL patients; 134 samples). Stromal cells (i.e., EC and MSC) were detected at relatively low frequencies in all control BM (16/16; 100%) and in most BCP-ALL follow-up samples (874/975; 90%), while they were undetected in BCP-ALL BM at diagnosis. In control BM samples, the overall percentage of EC plus MSC was higher in children than adults (p = 0.011), but with a similar EC/MSC ratio in both groups. According to the MRD status similar frequencies of both types of BM stromal cells were detected in BCP-ALL BM studied at different time points during the follow-up. Univariate analysis (including all relevant prognostic factors together with the percentage of stromal cells) performed in the discovery cohort was used to select covariates for a multivariate Cox regression model for predicting patient DFS. Of note, an increased percentage of EC (>32%) within the BCP-ALL BM stromal cell compartment at day +78 of therapy emerged as an independent unfavorable prognostic factor for DFS in childhood BCP-ALL in the discovery cohort—hazard ratio (95% confidence interval) of 2.50 (1−9.66); p = 0.05—together with the BM MRD status (p = 0.031). Further investigation of the predictive value of the combination of these two variables (%EC within stromal cells and MRD status at day +78) allowed classification of BCP-ALL into three risk groups with median DFS of: 3.9, 3.1 and 1.1 years, respectively (p = 0.001). These results were confirmed in two validation cohorts of childhood BCP-ALL (n = 74) (p = 0.001) and adult BCP-ALL (n = 40) (p = 0.004) treated at different centers. In summary, our findings suggest that an imbalanced EC/MSC ratio in BM at day +78 of therapy is associated with a shorter DFS of BCP-ALL patients, independently of their MRD status. Further prospective studies are needed to better understand the pathogenic mechanisms involved.

Published
2022
Full Text
View/download PDF

9. [Comparative analysis of blast immunophenotype between the diagnosis and relapse of childhood acute lymphoblastic leukaemia - implications for monitoring of minimal residual disease].

Author

Bulsa J, Sedek Ł, Sońta-Jakimczyk D, Mazur B, Sobol G, and Szczepański T

Subjects
Antigens, CD metabolism, B-Lymphocytes immunology, Biomarkers metabolism, Bone Marrow pathology, Cell Lineage, Child, False Negative Reactions, Female, Flow Cytometry, Humans, Immunophenotyping, Male, Neoplasm, Residual diagnosis, Recurrence, Retrospective Studies, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology
Abstract

Purpose: The aim of the present study was to compare the blast immunophenotype of acute lymphoblastic leukaemia (ALL) at diagnosis and at relapse and to define the most frequent shifts in marker expression., Patients and Methods: Bone marrow samples from 14 patients were analyzed by flow cytometry both at diagnosis and at relapse - in 12 patients with B-cell precursor (BCP)-ALL and in 2 patients with T-ALL., Results: The conversion in blast immunophenotype was observed in 12 out of 14 patients (86%). Antigen CD34 turned out to be the most unstable antigen - the shift in the signal expression was present in 57% of BCP-ALL and in both T-ALL cases. Regarding B-lineage markers, the shifts most frequently concerned CD20 (shifts present in 41.5% of cases) and CD22 (27%). Among the T-lineage markers: CD3, CD4 and CD8 demonstrated the highest incidence of altered signal expression. On the other hand, the most stable antigen included CD19 and CD10 for the BCP-ALL group and CD1a, CD2, CD5, CD7 for T-ALL patients. Expression of HLA-DR, TdT and CD45 antigens remained unchanged in both BCP-ALL and T-ALL groups., Conclusions: The results of the present study support the requirement to monitor at least two different leukaemia specific antigen combinations for detection of MRD to prevent a false-negative result and to increase the effectiveness of monitoring minimal residual disease.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results